RVU.WA Stock - Ryvu Therapeutics S.A.
Unlock GoAI Insights for RVU.WA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $77.97M | $46.86M | $38.80M | $11.19M | $15.41M |
| Gross Profit | $58.39M | $29.31M | $21.40M | $-2,538,736 | $6.65M |
| Gross Margin | 74.9% | 62.5% | 55.1% | -22.7% | 43.1% |
| Operating Income | $-122,099,000 | $-100,948,000 | $-78,422,000 | $-103,783,000 | $-35,697,025 |
| Net Income | $-111,435,000 | $-92,112,000 | $-83,782,000 | $-79,078,000 | $-31,687,587 |
| Net Margin | -142.9% | -196.6% | -215.9% | -706.9% | -205.6% |
| EPS | $-4.82 | $-4.02 | $-4.57 | $-4.31 | $-1.89 |
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Visit WebsiteEarnings History & Surprises
RVU.WAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 18, 2025 | — | — | — | — |
Q2 2025 | May 22, 2025 | — | $-1.09 | — | — |
Q1 2025 | Mar 13, 2025 | — | $-1.52 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-1.10 | — | — |
Q3 2024 | Sep 11, 2024 | — | $-1.40 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.84 | — | — |
Q1 2024 | Mar 13, 2024 | — | $-1.20 | — | — |
Q4 2023 | Nov 30, 2023 | — | $-0.79 | — | — |
Q3 2023 | Sep 13, 2023 | — | $-1.23 | — | — |
Q2 2023 | May 16, 2023 | — | $-0.79 | — | — |
Q1 2023 | Mar 24, 2023 | — | $-0.46 | — | — |
Q4 2022 | Nov 24, 2022 | — | $-0.64 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.20 | — | — |
Q2 2022 | May 18, 2022 | — | $-1.45 | — | — |
Q1 2022 | Mar 15, 2022 | — | $-0.92 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-1.24 | — | — |
Q3 2021 | Sep 8, 2021 | — | $-0.13 | — | — |
Q2 2021 | May 12, 2021 | — | $-0.74 | — | — |
Q1 2021 | Mar 16, 2021 | — | $-0.61 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-0.72 | — | — |
Latest News
Frequently Asked Questions about RVU.WA
What is RVU.WA's current stock price?
What is the analyst price target for RVU.WA?
What sector is Ryvu Therapeutics S.A. in?
What is RVU.WA's market cap?
Does RVU.WA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RVU.WA for comparison